“…Positive correlations have been found with variables, such as stage, metastasis, or overall survival in some [8-10, 14, 20, 22, 27-29], but not all of the studies [6,11,13,14,17,19,24], while simultaneous expression of multiple ERBB receptors has been suggested as a better indicator of decreased survival [8,10]. Loss of Her-2 immunostaining has been considered as an indicator of neoplastic transformation potential in premalignant lesions [18,[30][31][32], although there are reports to the contrary [32,33].…”